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Abstract 
 
 
Background 
The use of left ventricular assist devices (LVAD) widely increased in the past decade due to 
the lack of donor organs and the rising prevalence of heart failure. This therapy should lead 
patients in good condition to heart transplantation (bridge to transplant) or improve their quality 
of life (destination therapy). LVAD support is nowadays considered as an alternative to heart 
transplantation, however improvement in exercise performance is inconsistently 
demonstrated. The current study sought to quantitate physical capacity prior and subsequent 
LVAD implantation in order to assess the impact of this therapy. 
 
Methods and Results 
This study is a quantitative, observational, prospective, mono-centric trial which aimed to 
assess exercise capacity and its changes prior and subsequent LVAD implantation, using 
cardiopulmonary exercise testing (CPET), in patients suffering from refractory end-stage heart 
failure undergoing LVAD therapy with HeartMate 3 between 2017 and 2018 at the cardiac 
surgery department at CHUV. 21 patients underwent LVAD therapy during the study period, 
yet only 5 were included. CPET were completed an average of 11 months following 
implantation. Although VO2max improved by approximately 30% subsequent LVAD 
implantation, from 9,60 ± 3,88 ml/kg/min to 12,46 ± 3,16 (t-test=-2,424; ddl=4; p=0,072), it was 
not statistically significant and remained considerably lower than predicted values. 
Nonetheless, improvement by at least one NYHA class was seen in 100% of patients, with 
80% improving by two classes. As a result of the limited study sample size, firm reliance lacks 
between patients related clinical parameters and the variability in improvement of peak VO2. 
 
Conclusion   
Whereas VO2max improves on LVAD support, but not significantly, it provides an adequate 
functional capacity suitable for daily living activities. Yet, the link between peak VO2, everyday 
tasks and quality of life requires further investigations in LVAD patients. Further studies should 
focus towards identifying predictive factors associated with lack of improvement in VO2max and 
exertional capabilities in order to proceed with LVAD treatment concordant with patients’ 
values, objectives and expectations. 
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Introduction 
 
Heart failure is a syndrome in which the heart fails to both provide the organism with sufficient 
blood flow and meet its need for oxygen in order to maintain an optimal physiological function 
(1)(2). This condition leads to a progressive deterioration of functional capacity and quality of 
life. (3) This syndrome is a major public health concern due to its dark prognosis, with a 5 year 
survival rate of 51,5% and 29,5% at 10 years (4), 2012 annual costs estimated to be $30.9 
billions in the USA (5) and its rising incidence and prevalence. The latter being approximately 
1-2% of the adult population in developed countries (1). In 2005 a study conducted by Meyer 
and al. demonstrated that the heart failure event rate was 64,9 per 100'000 adult inhabitants 
of Switzerland, with a predominant incidence in the population aged over 65 (6). This burden 
is likely to increase in the next decades (5), especially in the elderly group. This is probably 
due to the ageing population and a better management of myocardial infraction (7). 
 
Current state of the art treatment for end-stage heart failure is heart transplantation (8) but the 
shortage of organ donors and the growing waiting list result in an increasing discrepancy that 
needs to be balanced with other alternatives. This widening gap can be observed in the 
Swisstransplant annual reports between 2005 and 2017 with an increase of 235% of patients 
on the waiting list but a minor rise in heart transplants, from 33 to 40. This makes approximately 
1 graft for 2 potential recipients in 2005 and 1 graft for 4 potential recipients in 2017. Due to 
this tendency and the paucity of effective medical therapies (9)(10), alternative treatments are 
crucial to overcome this burden. 
 
Left Ventricular Assist Device (LVAD) is a pump which aims to unload the heart by pumping 
blood from the apex of the left ventricle and send it directly to the ascending aorta in order to 
restore an adequate blood flow which should allow improvement of the function of every organ. 
There are two major indications for a LVAD implantation: As a Bridge To Transplant (BTT), to 
increase the chance of getting a heart transplantation for the patients on the waiting list and 
as Destination Therapy (DT), for those who are not eligible for heart transplantation (11). It is 
nowadays considered as an alternative to heart transplantation (12).  
 
Since the first implantation of a LVAD by Dr. Liotta in 1963 in Houston (13), the use of this 
technology widely expanded as a treatment of advanced heart failure, with approximately 2500 
devices implanted every year (14). 
The rise in devices implantation can probably be explained by its undeniable efficacy in end-
stage heart failure therapy (15), devices technical development and miniaturization throughout 
years.  
 
The vast majority of recently implanted LVADs are continuous flow (CF) pumps, operating at 
a fixed speed, due to their life span up to 10 years (16), 1 and 2 year survival rate of 80% and 
70% respectively succeeding implantation (14), as well as the substantially decreased 
incidence of complications compared to pulsatile pumps (17)(18). The latest generation of CF-
LVAD is HeartMate 3 (Abbott Laboratories, Chicago, IL, USA), a fully magnetically levitated 
centrifugal-flow pump, which generates an intrinsic artificial pump pulse in order to potentially 
decrease systemic effects of loss of pulsatile flow (19). 
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LVAD support has become an effective therapy for end-stage heart failure as well as an 
alternative to heart transplantation but remains an invasive surgical procedure engendering 
significant human and economic resources investment. Existing literature emphasized the 
clinical benefits on physical capacity and quality of life succeeding LVAD implantation 
(3)(16)(20)(21), but none have been conducted in Switzerland. 
One important patient-centered outcome after permanent or semi-permanent mechanical 
circulatory support (MCS) is that exercise capacity should be suitable for daily living activities 
which should be correlated with an improved quality of life. In light of the increasing use of 
MCS and long term support duration, it is fundamental to objectify the impact of these devices 
using cardio-pulmonary exercise tests in order to demonstrate its clinical benefits on exercise 
capacity in patients suffering from end-stage heart failure. 
 
Research question 
What are the clinical outcomes on physical capacity of  LVAD implantation in patients with end-
stage heart failure? 
 
 
Methods 
 
Study design 
The study is a quantitative mono-centric observational prospective trial based in the cardiac 
surgery department at CHUV, including patients with end-stage heart failure that underwent 
LVAD implantation with HeartMate 3 between 2017 and 2018. The research was considered 
as risk category A and was conducted within the scope of the « Ordinance relative to the 
research on human beings » (HRO) in accordance with the Swiss law. 
 
Patient selection 
We selected patients implanted with HeartMate 3 who performed a pre-operative and a post-
operative CPET. Patients who performed a CPET prior LVAD implantation only were 
convocated in order to perform a post-operative CPET 8 to 12 months post-procedure. The 
post-operative clinical exercise tests, which are included in the routine follow-up of patients 
implanted with a LVAD, were carried out during the iterative medical check-ups through project 
leader’s daily clinical practice at CHUV. 
Inclusion criteria were: patient with end-stage heart failure eligible for LVAD implantation as a 
BTT or DT or BTC at CHUV, free and informed consent to participate in this study and age 
≥18 years. Exclusion criteria were: patients too hemodynamically unstable to undergo 
functional testing post-LVAD implantation, any other severe condition than heart failure in 
compromising the realization of a CPET and mobility-limited people. Every patient were 
ambulatory and in stable condition. 
 
Outcomes 
The primary outcome was to quantify physical capacity on patients with refractory end-stage 
heart failure undergoing LVAD therapy with HeartMate 3 between 2017 and 2018 at the 
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cardiac surgery department at CHUV, using clinical exercise tests post-surgery. The generated 
data was compared with the functional testing results prior LVAD implantation which allowed 
us to objectify and assess a potential change in participants’ physical performances and 
analyze the impact of this therapy. 
The study’s secondary endpoint was to correlate participants’ clinical parameters and 
concomitant comorbidities with the functional testing results in order to identify patient’s related 
factors which may influence the outcome. Hopefully, this could, in the future, guide decision-
making to proceed with LVAD treatment concordant with patient’s values, objectives and 
expectations. 
 
CPET 
In order to assess exercise capacity, participants performed a symptom-limited CPET, on a 
treadmill ergometer (Valiant 2, Lode BV, The Netherlands) or a cyclo-ergometer (Ergoselect 
200, Ergoline GmbH, Germany) with breath-by-breath ventilatory gas exchange measurement, 
following an individualized ramp stress protocol, pre- and post-LVAD implantation at CHUV.  
CPET belongs to the standard clinical evaluation of  patients with heart failure and is routinely 
done as part of the pre-LVAD and pre-transplant evaluation. It provides a global evaluation of 
the integrative exercise response involving the cardiovascular, pulmonary and musculoskeletal 
system (22). This clinical tool has seen an increase in its spectrum use, notably for the 
objective determination of functional capacity and evaluation of patient’s response to specific 
therapeutic interventions (22)(23)(24). 
Participants were encouraged to exercise until exertion which was quantified using the 
modified Borg Scale, during or immediately after CPET, with numeric values ranging from 0 to 
10. A rating of 0 suggests no feeling of exertion, values of 7 and higher are indicative of very 
hard, extremely hard and maximal exertion. 
 
Data collection and definitions 
Physiological data measured throughout CPET and recovery were oxygen uptake (VO2), 
ventilatory efficiency (VE/VCO2), respiratory exchange ratio (RER: the ratio of VCO2/VO2), VO2 
at anaerobic threshold, electrocardiographic (ECG) tracing and heart rate (HR). The ergo-
spirometry system was carefully calibrated on a regular basis.  
Physical capacity, functional capacity and exercise capacity were defined by the maximal 
amount of exertion a subject can sustain, and was clinically quantitated by measuring maximal 
oxygen uptake (VO2max or peak VO2) during CPET. VO2max is the gold standard measure to 
assess exercise capacity as it represents the maximal level of oxidative metabolism attainable 
involving large muscle groups (22). If a clear plateau was not achieved before symptom 
limitation of exercise, peak VO2, the highest VO2 achieved during the last 30 seconds of 
maximal exercise, was used as an estimation of VO2max and as an expression of physical 
capacity. The Wasserman/Hansen equation was used to calculate predicted VO2max. RER and 
the modified Borg rating of perceived exertion scale were used to assess the quality of the 
exercise effort. 
 
Participants’ baseline characteristics, concomitant co-morbidities, heart failure etiology, 
medication at discharge, NYHA class prior LVAD implantation, post-operative adverse events, 
exercise and gas-exchange variables of the pre-operative CPET were collected retrospectively 
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via the softwares “Soarian” and “Archimède” to create a database, while  post-operative NYHA 
class, peri- and post-operative adverse events, post-operative CPET’s exercise variables and 
gas-exchange variables were collected prospectively. Baseline characteristics and medication 
were collected at hospital discharge. Co-morbidities were defined by physician’s diagnosis at 
the time of LVAD implantation. Left-ventricular ejection fraction, pulmonary hypertension and 
valvulopathies were recorded from transthoracic echocardiography during the pre-LVAD 
evaluation. Post-operative NYHA class was collected during the medical follow-up at 9 months 
after discharge. Pump speed was optimized at the time of implantation, before discharge and, 
if necessary, during the iterative ambulatory LVAD controls based on clinical events. When 
several CPET were performed prior to LVAD implantation, we used the most exhaustive and 
nearest test to the date of surgery. 
 
Statistical analysis 
Data and statistical analysis were performed using Microsoft Excel (Microsoft Corporation, 
Redmond, WA, USA, Version 16.16.5) and IBM SPSS Statistics (IBM Corporation, Armonk, 
NY, USA, Version 25). Dichotomous variables are presented as percentage, continuous 
variables are presented as mean, ± standard deviation and median. Normality was tested 
using Shapiro-Wilk test. Pre- and post-operative CPET results were compared using a Paired 
Student’s t-test in order to demonstrate whether differences in clinical exercise testing 
parameters occurred after LVAD implantation. Means between parameters prior and 
subsequent LVAD implantation were compared with a Paired Student’s t-test for normally 
distributed quantitative variables and a Wilcoxon signed-rank test as the non-parametric 
equivalent. The Pearson’s correlation, contingency coefficient, linear regression and one-way 
ANOVA were used to measure the association between clinical parameters and changes in 
peak VO2 as well as NYHA functional class. Statistical significance was defined as p < 0,05. 
 
Ethical consideration 
This research project was approved by the Swiss Ethics Committee on research involving 
humans (CER-VD) and was conducted in accordance with the Declaration of Helsinki (BASEC 
ID: 2017-01425). All participants signed informed consent. 
 
 
Results 
 
Between January 2017 and September 2018, 21 patients underwent LVAD implantation with 
HeartMate 3 at CHUV. Two patients didn’t perform a CPET at CHUV prior LVAD implantation, 
five patients were bridged to transplantation before undergoing the post-operative CPET, two 
patients died before performing the post-procedure CPET, six patients were not fit to perform 
the post-operative CPET, one didn’t perform the post-procedure CPET before study 
termination and were therefore excluded. Thus, five patients performed CPET both pre- and 
post-LVAD implantation, with anaerobic threshold reached, and were included in the analysis. 
Patient’s selection is displayed on Figure 1. 
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Figure 1. Patient cohort. 
 
 
 
Study population consisted of 5 (100%) males. Average age at LVAD implantation was 56,80 
± 12,77 years. Baseline characteristics of the study cohort are presented in Table 1. All patients 
suffered from end-stage heart failure with a mean ejection fraction of 22,20% ± 6,35%. Heart 
failure etiology prior LVAD implantation was ischemic cardiopathy in 3 patients (60%) and non-
ischemic in 2 patients (40%). Two patients (40%) had cardiac surgeries prior LVAD 
implantation, those being mitral valve replacement (n=1, 20%) and coronary artery bypass 
graft (n=1, 20%), moreover 80% (n=4) had a cardiac resynchronization therapy implantable 
cardioverter defibrillator (CRT-D). LVAD was implanted as BTT in 3 patients (60%), whereas 
1 patients was implanted as DT (20%) and 1 was implanted as BTD (20%). Surgery was 
elective for 4 patients (80%) while 1 patient (20%) underwent emergency surgery for a 
cardiogenic shock. Mean operative duration was 219,60 ± 44,46 minutes and 77,80 ± 13,16 
minutes for extracorporeal circulation duration. Three patients (60%) underwent concomitant 
cardiac procedure at time of surgery, being closure of atrial sepat defect (n=1, 20%), left atrial 
appendage exclusion (n=1, 20%) and extracorporeal membrane oxygenation (ECMO) 
implantation (n=1, 20%). Median length of hospital stay was 37 days (range: 21–131) with a 
median stay of 4 days (range: 2–66) in the intensive care unit (ICU). Pump settings were 
adjusted ambulatory, attaining mean values of 4,42 ± 0,47 L/min for pump flow, 5470 ± 139,64 
RPM for pump speed, 4,40 ± 0,54 Watts for pump power and 4,44 ± 1,03 for pulsatility index 
by the time of the postoperative CPET. Four patients (80%) benefited from cardiac 
rehabilitation at a mean of 28,25 ± 10,21 days succeeding surgery and for a mean stay of 
17,75 ± 3,40 days, with a program focusing on endurance, isometric training, gymnastic and 
calisthenics.  
 
 
 
 
21 patients implanted with Heartmate 3 at CHUV between January 2017 and September 2018
2 patients didn’t perform a 
CPET prior LVAD 
implantation at CHUV
2 patients performed a pre-
and a post-operative CPET
17 patients performed a 
CPET  at CHUV prior LVAD 
implantation only
5 patients were included in the study
5 patients were transplanted
before performing the post-
operative CPET
2 patients died before
performing the post-operative
CPET
6 patient had contraindication to 
perform the post-operative
CPET 
10 patients were convocated
to perform a post-operative
CPET
1 patient was
bridged to 
transplantation
1 patient died
after surgery
1 patients performed post-
procedure CPET after
study termination
3 patients performed CPET 
pre- and post-LVAD
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Table 1. Baseline characteristics N=5 
Characteristics Values 
Age (years) 56,80 ± 12,77 
Male, n (%) 5  (100,00) 
Weight (kg) 77,20 ± 15,06 
Height (cm) 175,40 ± 10,26 
Body mass index (kg/m2) 24,98 ± 4,06 
Heart failure etiology, n (%)    
 Ischemic 2  (40,00) 
 Valvular + rhythmic 1  (20,00) 
 Ischemic + valvular + rhythmic 1  (20,00) 
 Toxic 1  (20,00) 
Cardiovascular risk factors, n (%)    
 Tobacco use 3  (60,00) 
 Arterial hypertension 3  (60,00) 
 Dyslipidemia 4  (80,00) 
 Obesity 1  (20,00) 
 Alcohol consumption 2  (40,00) 
Comorbidities, n (%)    
 Atrial fibrillation 4  (80,00) 
 Coronary artery disease 3  (60,00) 
 Valvulopathy* 5  (100,00) 
 COPD 1  (20,00) 
 Obstructive sleep apnea 2  (40,00) 
 Kidney failure 1  (20,00) 
Medical history, n (%)    
 Myocardial infarction 4  (80,00) 
 Cardiogenic shock 3  (60,00) 
 Cardiopulmonary arrest 1  (20,00) 
 Previous cardiac surgeries 2  (40,00) 
Medication at discharge, n (%)    
 Angiotensin-converting enzyme inhibitor 4  (80,00) 
 Angiotensin II receptor antagonist 1  (20,00) 
 Anti-aldosterone 3  (60,00) 
 β-blocker 3  (60,00) 
 Diuretics 4  (80,00) 
 Anticoagulation** 5  (100,00) 
 Antiplatelet 3  (60,00) 
 Lipid-lowering drugs 4  (80,00) 
 Amiodarone 1  (20,00) 
Echocardiographic data    
 LVEF (%) 22,20 ± 6,10 
 Systolic pulmonary artery pressure (mmHg) 54,40 ± 15,90 
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 Diastolic pulmonary artery pressure (mmHg) 27,40 ± 9,02 
 Mean pulmonary artery pressure (mmHg) 37,60 ± 8,91 
LVAD data    
 Bridge to transplant, n (%) 3  (60,00) 
 Destination therapy, n (%) 1  (20,00) 
 Bridge to decision, n (%) 1  (20,00) 
 Speed (rpm) 5470,00 ± 139,64 
 Flow (L/min) 4,42 ± 0,47 
 Power (W) 4,40 ± 0,54 
 Pulsatility index 4,44 ± 1,03 
 
* Valvulopathy was defined by physicians’ diagnose based on echocardiography’s data prior LVAD 
implantation. 60% of patients (n=3) had a concomitant mitral regurgitation (MR) and tricuspid 
regurgitation (TR) while 20% (n=1) had a concomitant aortic regurgitation (AR) and TR. 20% (n=1) had 
a concomitant MR, TR and AR. 
** One patient (20%) had dual anticoagulant therapy (vitamin K antagonist and Heparin). 
 
Postoperative adverse events ensued in four patients (80%), with a mean of 3 ± 3,54 
complications per patients during their initial hospitalization, the most common being post-
surgical bleeding [5 episodes (33,34%); 2 patients (40%)], infectious events [4 episodes 
(26,67%); 2 patients (40%)], including 3 episodes (20%) of non-LVAD localized infection (n=2, 
40%) and a septic shock (6,67%) (n=1, 20%), and supraventricular arrhythmia [2 episodes 
(13,34%); 2 patients (40%)]. One ischemic stroke (6,67%) occurred in 1 patient (20%) and 
right heart failure (6,67%) was diagnosed in 1 patient (20%). Re-hospitalization occurred in 
80% of patients (n=4), with a mean of 1,50 ± 0,58 readmissions per patients, at a median time 
of 125,5 days (range: 32–324) succeeding LVAD implantation and for a median stay of 6 days 
(range: 3–56). Re-hospitalization were resulting from driveline infection [4 episodes (66,67%); 
2 patients (40%)] ventricular arrhythmia [1 episodes (16,67%); 1 patients (20%)] and bleeding 
[1 episode (16,67%); 1 patients (20%)]. Reported postoperative adverse events and causes of 
readmission are listed on table 2. Two patients (40%) underwent revision surgeries at a median 
time of 5 days (range: 0–18) after LVAD implantation, for clot removal in the context of a 
iatrogenic tamponade (n=1, 20%) and ECMO withdrawal along with surgical evacuation of a 
retrosternal hematoma and a left hemothorax (n=1, 20%). 
 
Table 2. Adverse events  N=5 
Immediate and delayed adverse events N° of patients % of patients N° of events 
Infection    
 Non-LVAD localized infection 2 40,00 3 
 Driveline infection 2 40,00 4 
 Sepsis 1 20,00 1 
Arrhythmia    
 Supraventricular 2 40,00 2 
 Ventricular 1 20,00 1 
Bleeding* 3 60,00 6 
Right heart failure 1 20,00 1 
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Ischemic stroke 2 40,00 2 
Cardiac tamponade 1 20,00 1 
Pleural effusion 1 20,00 1 
Kidney failure 1 20,00 1 
 
* Post-surgical bleedings included hemopericardium [1 episode, (20%); 1 patient, (20%)], left 
hemothorax (2 episodes, 40%) together with retrosternal hematoma (1 episode, 20%) and 
gastrointestinal bleeding (1 patient; 20%). Readmission for hemorrhage included a post-traumatic acute 
subdural hematoma [1 episode, (100%); 1 patient (20%)]. 
 
Mean pre-operative NYHA class was 3 while mean post-operative NYHA class was 1,20 ± 
0,45 (Z=-2,121; p=0,034). Hence, corresponding to an improvement of 1,80 ± 0,45 per patients 
in their NYHA functional class. Overall, 1 patient (20%) improved by one its NYHA functional 
class, while 80% of patients (n=4) improved by two NYHA classes after LVAD implantation. 
Comparison in NYHA class pre- and post-LVAD implantation is displayed on Figure 2. Baseline 
characteristics, co-morbidities, medical history, heart failure etiology, therapeutic project (BTT, 
DT or BTD), echocardiographic data, peri- and post-operative adverse events above-
mentioned were not statistically correlated with improvement in NYHA functional class 
subsequent LVAD-implantation, probably due to the limited sample size. 
 
Figure 2. 
 
 
 
Pre-LVAD implantation NYHA class: NYHA III (n=5) 
Post-LVAD implantation NYHA class: NYHA I (n=4), NYHA II (n=1) 
 
Median time between baseline CPET and LVAD implantation was 57 days (range: 15–539). 
The pre-operative CPET was performed on a bicycle ergometer on 80% of patients (n=4) and 
on a treadmill ergometer on 20% of patients (n=1), following an individualized ramp protocol. 
Prior LVAD implantation, mean VO2max was 9,60 ± 3,88 ml/kg/min corresponding to 
approximately 36,60 ± 15,47% of the predicted VO2max. Patients were able to exercise an 
average of 05:54 ± 03:15 minutes and mean work load achieved was 4,98 ± 3,56 metabolic 
equivalents (METs). Every patient achieved adequate exercise effort as demonstrated by a 
80,00%
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Pre- and post-LVAD implantation NYHA 
class distribution
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mean respiratory exchange ratio of 1,11 ± 0,16 on stress completion. Perceived exertion 
couldn’t be assessed in 2 patients due to language barrier, however, quality of effort was rated 
with a mean of  7 ± 3 for dyspnea and 5 ± 4 for muscular fatigue on the modified Borg scale. 
Participants showed an impaired gas exchange during the pre-operative CPET as evidenced 
by an elevated VE/VCO2 slope (55,86 ± 36,68). Mean anaerobic threshold was reached at 
27,80 ± 14,06% of predicted VO2max. 
 
Figure 3. Pre- and post-operative VO2max. 
 
 A. 
 
 
 B. 
 
 
Mean change in VO2max is represented by the bold dark blue line in Figure 3 B. 
 
Post-procedure CPET was performed at a median time of 279 days (range: 194–623). A 
bicycle ergometer was used in 4 patients (80%) while 1 (20%) performed the post-operative 
CPET on a treadmill ergometer. Every patient followed a manual ramp protocol. VO2max 
improved subsequent LVAD implantation, from 9,60 ± 3,88 ml/kg/min to 12,46 ± 3,16 
ml/kg/min, corresponding to a mean VO2max increase of 2,86 ± 2,64 ml/kg/min per patients, 
however without being statistically significant (t-test=-2,424; ddl=4; p=0,072). Peak oxygen 
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consumption remained although considerably lower than predicted values (44,80 ± 9,39%; t-
test=-1,374; ddl=4; p=0,242). Mean ratio of minute ventilation to carbon dioxide production 
(VE/VCO2) slope was 38,98 ± 4,29. Average test duration was 06:33 ± 02:39 minutes, which 
is 00:39 ± 00:88 seconds longer than pre-LVAD, and mean work load achieved was 5,30 ± 
2,64 METs. Three out of five patients (60%) were able to complete the modified Borg scale of 
perceived exertion. Quality of exercise effort was similar to the pre-operative values, with a 
mean RER of 1,14 ± 0,14 and a rating of 6 ± 2 for dyspnea along with 5 ± 3 for muscular fatigue 
at exercise termination. Mean anaerobic threshold was reached at 29,56 ± 5,47% of predicted 
VO2max.Pre- and post-LVAD VO2max is displayed on figure 3 and 4. CPET results are presented 
in table 3. 
 
Table 3. Cardiopulmonary exercise test result prior and succeeding LVAD implantation (N=5) 
  Pre-LVAD Post-LVAD p value 
Time between LVAD placement and CPET 
(days) 189,20 ± 231,33 346,00 ± 166,74 – 
CPET modality        
 Treadmill ergometry, n (%) 1  (20,00) 1  (20,00) – 
  Speed (km/h) 5,80 5,10 – 
  Meters 742,00 602,00 – 
  Slope (%) 15,00 14,00 – 
 Bicycle ergometry, n (%) 4  (80,00) 4  (80,00) – 
  Peak workload (W) 52,00 ± 18,49 71,75 ± 25,81 0,062 
  Predicted peak workload (W) 151,75 ± 10,56 166,25 ± 32,84 0,391 
  % Predicted peak workload (%) 34,25 ± 12,26 43,25 ± 12,89 0,168 
 Manual ramp protocol, n (%) 8  (100,00) 8  (100,00) – 
Exercise parameters        
 Exercise time (min) 05:54 ± 03:15 06:33 ± 02:39 0,383 
 RER 1,11 ± 0,16 1,14 ± 0,14 0,255 
 VO2max (ml/kg/min) 9,60 ± 3,88 12,46 ± 3,16 0,072 
 Predicted VO2max (ml/kg/min) 26,82 ± 4,39 27,56 ± 4,29 0,727 
 % Predicted VO2max (%) 36,60 ± 15,47 44,80 ± 9,39 0,242 
 METs 4,98 ± 3,56 5,30 ± 2,64 0,602 
 VE/VCO2 slope 55,86 ± 36,68 38,98 ± 4,29 0,329 
 AT as % predicted peak VO2 (%) 27,80 ± 14,06 29,56 ± 5,47 0,784 
Vital signs        
 Peak heart rate (beats/min) 103,40 ± 16,07 105,20 ± 22,83 0,79 
 Predicted peak heart rate (beats/min) 163,80 ± 12,68 162,20 ± 12,77 0,016 
 % Predicted peak heart rate (%) 63,00 ± 8,54 65,00 ± 14,16 0,616 
NYHA class 3,00 ± 0,00 1,20 ± 0,45 0,034 
 
Patients with obesity (F=6,418; ddl=4; p=0,085) medical history of coronary artery disease 
(F=5,606; ddl=4; p=0,099), cardiogenic shock (F=5,606; ddl=4; p=0,099), ischemic HF etiology 
(F=5,606; ddl=4; p=0,099) and ventricular arrhythmia as cause of rehospitalization (F=6,418; 
ddl=4; p=0,085) tend to have lower post-operative VO2max values. Furthermore, the number of 
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hospital re-admission negatively correlated with improvement in VO2max subsequent LVAD 
implantation (r=-0,754; r-squared=0,569; p=0,141). Though, statistical significance was not 
observed as a result of the limited study sample, hence skewing correlation between 
parameters and precluding firm conclusions. 
 
 
Discussion 
 
In the present study, exercise capacity and its changes were assessed prior and after LVAD 
implantation, using CPET, in patients suffering from end-stage heart failure supported with a 
HeartMate 3. The major finding from this current study suggest that VO2max improves modestly 
but not significantly subsequent LVAD support. Furthermore, peak VO2 fails to normalize to 
predicted values corrected for gender and age. Indeed, physical capacity improved from 9,60 
± 3,88 to 12,46 ± 3,16, corresponding to a mean VO2max increase of 2,86 ± 2,64 ml/kg/min per 
patients, though remained subnormal, approximately 44,80 ± 9,39% of predicted VO2max. 
Divergent results were reported in previous studies assessing physical capacity prior and 
subsequent CF-LVAD support. Accordingly, Benton and al. established a significant increase 
in peak VO2 from 11,6 ± 5,0 ml/kg/min to 15,4 ± 3,9 ml/kg/min at approximately 6 months after 
LVAD implantation (25). Dunlay and al. recorded a modest increase of 0,9 ml/kg/min in peak 
VO2 post-LVAD (11,5 ± 2,5 ml/kg/min to 12,4 ± 2,8 ml/kg/min), but was not statistically 
significative (26). Leibner and al found that peak VO2 remained constantly low throughout 
repeated exercise testing (11,2 ± 3,0 ml/kg/min at baseline, 12,7 ± 3,5 ml/kg/min after 3-6 
months, 10,7 ± 2,7 ml/kg/min after 1 year and 11,2 ± 1,7 ml/kg/min after more than 1 year) 
(27). On the other hand, de Jonge and al. highlighted that peak VO2 improves over time, with 
values attaining 21,3 ± 3,8 ml/kg/min at 8 months and 24,2 ± 4,8 ml/kg/min at 12 months in a 
younger cohort of patients (age: 37 ± 12 years) who underwent intensive training program, 
though didn’t compare these values with pre-implantation data (21). 
 
Though an improvement in peak VO2 of approximately 30% has been assessed subsequent 
LVAD implantation, the functional impact of this value, especially throughout patients daily 
living activities, as its influence on quality of life remains unknown. This increase in peak VO2 
remains nevertheless higher compared to parenteral inotropic therapy, showing improvement 
of 11,24% after levosimendan infusion (9,8 ± 1,7 ml/kg/min to 11,0 ± 1,9 ml/kg/min; p<0,005), 
an inodilator agent (28). The clinical benefits of improvement in VO2max are well documented 
in the literature (reduced risk of all-cause and cardiovascular mortality as hospitalization in 
patients with chronic systolic heart failure) (29), nonetheless objective data concerning the 
increase in physical capacity related to this improvement is lacking. Previous studies displayed 
a linear correlation between six-minute walking distance (6MWD) and VO2max, we can thus 
extrapolate from these data that an approximate increase of 3 ml/kg/min in peak VO2 is 
associated with an improvement of 100 meters in the 6MWD (30)(31). However, these 
estimations shall not be generalized when assessing individuals, especially in the LVAD 
population due to their heterogeneity and their multimorbid traits. Nevertheless, we assume 
that LVAD therapy provided an adequate functional capacity suitable for daily living activities. 
Accordingly, 80% of patients (n=4/5) in our study cohort reported no impairment in walking on 
a flat surface, being able to walk up a median of 3 flight of stairs without pauses (range 1–6), 
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60% (n=3/5) declared practicing a light physical activity, and 20% (n=1/5) reported returning 
to part time work (50% activity) throughout the routine follow-up around time of the post-
operative CPET. Unfortunately, the absence of data on functional capacity prior LVAD 
implantation precludes comparisons, hence the ability to draw conclusions. Further 
investigations should be conducted in order to assess the improvement in functional status 
and quality of life related to increase in VO2max in LVAD patients. 
 
We found no differences in post-procedure VO2max in patients supported with a LVAD as BTT, 
DT or BTC and when stratified by heart failure etiology. Though, patients with non-ischemic 
heart failure etiology (F=5,606; ddl=4; p=0,099) and higher pre-LVAD LVEF (r=-0,468; r-
squared=0,219; p=0,426) tend to correlate with greater post-operative VO2max values, but not 
significantly. Several studies identified factors associated with improvement in VO2max. The 
latter being pulsatility index, pump power, pump speed, peak heart rate and exercise training 
(21)(32). Since our study did not aim to assess repeated CPETs over time, we cannot draw 
conclusions concerning the effect of training on VO2max. A mild correlation was evidenced 
between pump flow (r=0,455; r-squared=0,207; p=0,442), pump power (r=0,557; r-
squared=0,310; p=0,329), pulsatility index (r=0,471; r-squared=0,222; p=0,424) at CPET and 
improvement in peak VO2, though not statistically significant. Nonetheless, participation in 
cardiac rehabilitation and its duration did not correlate with improvement in VO2max. 
One patient underwent CPET on a treadmill ergometer and showed higher post-implantation 
VO2max (16,2 ml/kg/min) compared to those who underwent bicycle ergometry (11,53 ± 2,73 
ml/kg/min). These result is similar to the ones displayed by Haft and al. (peak VO2 of 15,6 
ml/kg/min on LVAD support) who tested their study group on a treadmill ergometer (33). The 
use of treadmill ergometry should be taken into account since it requires greater muscle mass, 
hence explaining these higher values. 
 
The suboptimal oxygen consumption may be partially explained by the fixed pump speed 
which limits the ability to increase cardiac output during exercise, thus failing to adapt to the 
increasing hemodynamic needs of exercise. Nevertheless, pump-generated blood flow 
together with native cardiac output increase during exercise under constant pump speed (up 
to approximately 1L/min and 3L/min respectively at maximal effort) due to augmented preload 
and cardiac contractility, hence contributing to a moderate increase in total cardiac output. 
However this response remains insufficient to normalize VO2max (34)(35). Previous studies 
highlighted that higher LVAD pump speed increased cardiac output which was associated with 
higher peak VO2, together with improvement in peak workload and exercise duration (36)(37). 
Pump speed was optimized ambulatory and at rest, in order to efficiently unload the left 
ventricle while averting suction events, but was not actively manipulated for the present study. 
Thus, conclusions could not be drawn concerning the relationship between pump speed and 
physical capacity. Despite the failure to normalize peak oxygen consumption to predicted 
levels, several studies reported that patients had improved quality of life and increased 
subjective exercise capacity following LVAD implantation (38). In the present study, self-
reported NYHA functional class at 9 months improved significantly by one class in 20% of 
patients and by two classes in 80% of patients. Furthermore, Benton and al. highlighted that 
improvement by at least two NYHA class was achieved by 91,4% of patients, with 34,3% 
improving by three class (25). This marked divergence between subjective improvements in 
functional class and moderate increases in peak VO2 suggest that improvement in the latter 
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depends upon other determinants than augmented cardiac output. Accordingly, patients’ 
concomitant co-morbidities including obstructive and restrictive lung diseases, persistent 
pulmonary hypertension, right heart failure, peripheral vascular disease, endothelial 
dysfunction, skeletal muscle diseases and muscle deconditioning may also contribute to the 
inability to increase VO2max to predicted values (3)(12). In order to minimize the impact of 
deconditioning, post-procedure CPETs were performed 8 to 12 months subsequent LVAD 
implantation, hence allowing optimal postoperative convalescence. 
 
A substantial improvement in ventilatory response to exercise (VE/VCO2 slope) has been 
assessed subsequent LVAD implantation, although not statistically significant. Accordingly, 
VE/VCO2 slope decreased from 55,86 ± 36,68 prior LVAD implantation to 38,98 ± 4,29 post-
procedure (t-test=1,112; ddl=4; p=0,329). However, it remained elevated (VE/VCO2 slope ≥ 
34), which is associated with a poor prognostic, notably due to higher cardiac related mortality 
and re-hospitalizations (39). 
CF-LVAD support causes considerable changes in hemodynamic physiology which leads to 
specific adverse events, hence frequent re-hospitalization (40). Common predominant 
complications stated in the literature are ischemic stroke, pump thrombosis, cardiac 
arrhythmia, right heart failure, driveline infection and bleeding (including surgical and 
gastrointestinal bleeding), the latter being the most frequent adverse event (11)(14)(17). Six 
unexpected re-hospitalization occurred in 80% of our discharged patients during the first year 
succeeding implantation. Re-admissions were owed to infection, arrhythmia and bleeding. 
However, our study cohort didn’t experience pump thrombosis nor gastrointestinal bleeding 
and only one re-hospitalization was due to an hemorrhagic event at approximately 1 month 
post-LVAD implantation. Plausible explanations could be the inherent characteristics of the 
HeartMate 3, thought to decrease shear stress with larger gaps in the rotor in order to avert 
pump thrombosis and reduce the risk of acquired von Willebrand disease. Furthermore, the 
introduction of an intrinsic artificial pump pulse (approximately 25mmHg, every 2 seconds) 
should avert stasis in the pump and potentially prevent arteriovenous malformation in the 
gastrointestinal tract, which are a major cause of hemorrhage (17)(19). Two ischemic strokes 
occurred in 2 patients (40%) whose one was due to anticoagulation reversal in the context of 
a post-traumatic subdural hematoma. Considering the wide blood flow path of the HeartMate 
3, an intracardiac thrombus may have embolized leaving the pump unobstructed, though a 
thrombosis developed within the device may unlikely embolize owing to the centrifugal flow. 
Current data involving HM III shows similar rates of bleeding but lower risk of pump thrombosis, 
lower incidence of ischemic stroke and higher survival free of disabling strokes or reoperation 
to replace or remove the device compared to former CF-pumps (17)(41). Furthermore, we 
found a strong correlation (C=0,707, p=0,025) between dual anticoagulant therapy associated 
with antiplatelet therapy (n=1, 20%) and the onset of non-surgical hemorrhagic events (n=1, 
16,67%). Thus, the perspective of low-intensity anticoagulation protocols, which should reduce 
incidences of bleeding events, might be beneficial in the future when carefully balanced with 
the patient’s risk of thrombo-embolic events. 
 
Study limitations, Strengths and Clinical Implications 
In the context of a Master’s thesis, the present study was mono-centric, thus the limited sample 
size was defined by the local population’s volume and by the time-limited research. The post-
operative CPETs were performed as a routine clinical follow-up, hence time between LVAD 
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implantation and CPET varied from 8 to 12 months in order to allow an optimal postoperative 
convalescence and only a subset of patients who underwent LVAD implantation between 2017 
and 2018 could be selected. The post-operative CPETs were performed by patients 
hemodynamically stable and in fairly good condition, which could be a selection bias as it isn’t 
representative of the population supported with LVAD. Furthermore, only participants who 
underwent CPET prior LVAD implantation were selected to perform the post-operative CPET. 
Thus, our study cohort represents 23,81% of every patients receiving LVADs at our center 
during the study period. Moreover, our study was limited by a narrow statistical analysis and 
the possibility of confounding bias due to the low sample size, which precluded firm 
conclusions. The majority of patients included in our study sample (3 out of 5) underwent 
multiple pre-operative CPETs (mean: 2,4; SD: ± 1,67; range: 1–5) which might have influenced 
the post-operative exercise testing’s results due to increased test familiarity. On the other 
hand, exercise limiting non-cardiac comorbidities may have influenced submaximal tests. 
CPET was performed on a bicycle ergometer by 4 patients prior LVAD implantation and post-
procedure while one underwent CPET on a treadmill ergometer. Some data suggest that 
bicycle ergometry presents a lower peak oxygen content of approximately 6-25%, due to lower 
muscle mass recruitment, compared to treadmill exercise testing (22)(24), which might have 
induced a measurement bias. Moreover, manual stress protocols were used in order to be 
concordant with patients’ functional capabilities, thus varied within then study group which may 
have affected measurement of peak VO2. 
 
Nevertheless, this study had several significant strength. First, time between LVAD 
implantation and post-procedure CPET was approximately 11,38 ± 5,48 months, hence 
reducing the limiting effect of skeletal muscles atrophy and diaphragm weakness on peak 
oxygen consumption (3)(25). Second, every subject were implanted with the latest generation 
of LVAD, HeartMate 3, which allowed us to assess the impact of this therapy as an 
homogenous LVAD system, thus avoiding biases due to intrinsic characteristics of different 
pump models. Furthermore, every patient had similar preoperative management procedures 
and almost all benefited from cardiac rehabilitation after LVAD implantation. Third, LVAD 
optimization together with ventricular septal position, left ventricular unloading and symptoms 
management were achieved as part of the iterative routine medical check-ups, which is more 
reflective of real-life scenarios. Moreover, our patient’s collective may differ from abroad 
studies who used an ideal sample, due to a higher morbidity and multiple co-morbidities, which 
leads to a flexibility in the eligibility for LVAD implantation. Thus, being more representative of 
the heart failure population.  
 
The present study provides additional data concerning LVAD’s impact on physical capacity 
which allows to justify the direct and indirect costs of the device implantation, maintenance, 
and the invasive surgical procedure of this therapy. Enhancement in functional capacity shall 
impact on patient’s daily living activities and quality of life, on life years gained and 
improvement in symptoms compared to medical therapy. Although improvement in physical 
capacity was clearly objectified, it was not statistically significant. LVAD support restores 
cardiac output and adequate peripheral blood flow, however remains insufficient to normalize 
VO2max. This suggest that other pathophysiological mechanisms underlie the incomplete 
recovery which LVAD therapy is unable to fully reverse. Efforts should be directed toward this 
concern, especially in destination therapy patients, in order to achieve satisfactory long-term 
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results. Moreover, this study allowed us to identify clinical parameters correlated with a poorer 
outcome but weren’t conclusive due to the limited study sample size. Further investigations 
focusing on these variables should be conducted in order to guide decision-making to proceed 
with LVAD treatment concordant with patients’ values, objectives and expectations. 
 
 
Conclusion 
 
Patients LVAD therapy have seen their NYHA functional class improve significantly, however 
changes in their physical capacity could not be statically assessed. By improving VO2max by 
approximately 30%, this therapy should lead successfully patients to heart transplantation 
(BTT), improve their quality of life (DT) and restore an adequate functional capacity suitable 
for everyday activities. Further studies should investigate the subjective improvement in 
exercise capacity, using standardized questionnaires, in order to correlate the results with 
post-procedure VO2max and to fully assess the impact of LVAD support on quality of life. No 
firm conclusions could be made concerning the influence of patients related clinical parameters 
on peak VO2 in the present study due to the limited sample size. Further research should focus 
on identifying predictive factors influencing the outcome of this therapy in order to sharpen 
patients’ selection. 
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